Studies have shown that MIAT (ranked ninth) is highly expressed in various solid tumors in humans and promotes AML progression by negatively regulating miR-495, which may be a promising therapeutic target in patients with AML (Wang et al., 2019). This evidence concerns the gene MIAT and acute myeloid leukemia.